Street Recommendation Roundup: Nike, Inc. (NYSE:NKE), Kura Oncology Inc (NASDAQ:KURA)

In the most recent session, Nike, Inc. (NYSE:NKE) shares have traded -0.18%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $-1.09 away from the 50-day moving average of $55.98 and $1.23 away from the 200-day moving average of $53.66. From a different angle, the stock has been recently recorded -9.02% off of the 52-week high of 60.33 and +12.00% removed from the 52-week low of 49.01. 

Currently, Nike, Inc. Common Stock has a price to earnings ratio of 22.90. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 2.02.

Price Target Update

Analysts polled by Thomson Reuters have set a consensus target price of $62.36 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.

Kura Oncology Inc (NASDAQ:KURA) shares have a current ABR (average broker recommendation) of 1. This recommendation is offered by Zacks Research. The rating lands on a sliding numerical scale from 1 to 5. A recommendation of 5 would indicate a Strong Sell, and a 1 would signify a Strong Buy. The mean rating may help provide a general sense of analyst sentiment on company shares.

Sell-side analysts taken into consideration by Zacks have also provided price target estimates on shares of Kura Oncology Inc (NASDAQ:KURA). The highest current target is $16. The lowest price target out of the polled analysts is presently $15. The consensus target price is currently noted at $15.5. Analysts may employ various techniques to help predict future stock price levels.

On the earnings front, Kura Oncology Inc (NASDAQ:KURA) is expected to post quarterly earnings per share of $-0.46. This is the current consensus figure provided by Zacks. Investors and analysts will be looking for the company to next post earnings on or around 2017-05-10. Kura Oncology Inc (NASDAQ:KURA) most recently reported quarterly EPS of $-0.38 for the quarter ending 2016-12-31. The gap between the actual and the projected estimate leading up to earnings created a surprise factor of 2.56%.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment